Improvement or no decline in FVC | Decline in FVC | |||
Nintedanib | Placebo | Nintedanib | Placebo | |
Subjects n | 158 | 38 | 480 | 385 |
Age years | 66.3±7.9 | 67.6±8.2 | 66.7±8.2 | 66.9±7.9 |
Male | 126 (79.7) | 31 (81.6) | 381 (79.4) | 303 (78.7) |
Race | ||||
White | 99 (62.7) | 24 (63.2) | 261 (54.4) | 224 (58.2) |
Black | 1 (0.6) | 0 (0.0) | 1 (0.2) | 0 (0.0) |
Asian | 38 (24.1) | 11 (28.9) | 156 (32.5) | 117 (30.4) |
Missing# | 20 (12.7) | 3 (7.9) | 62 (12.9) | 44 (11.4) |
Former or current smoker | 130 (82.3) | 28 (73.7) | 334 (69.6) | 273 (70.9) |
Weight kg | 82.6±15.4 | 83.9±18.0 | 78.1±16.8 | 78.1±16.3 |
Time since diagnosis of IPF years | 1.6±1.4 | 1.5±1.1 | 1.7±1.4 | 1.6±1.3 |
FVC mL | 2850±782 | 2949±827 | 2669±744 | 2706±806 |
FVC % pred | 81.6±18.1 | 84.4±19.8 | 79.1±17.4 | 78.8±18.0 |
DLCO % pred | 47.5±12.3 | 50.7±17.1 | 47.4±13.9 | 46.6±12.9 |
Diagnostic subgroup | ||||
No honeycombing on HRCT and no biopsy | 50 (31.7) | 8 (21.1) | 163 (34.0) | 117 (30.4) |
Honeycombing on HRCT and/or confirmation of UIP by biopsy | 108 (68.4) | 30 (79.0) | 317 (66.0) | 268 (69.6) |
Data are presented as mean±sd or n (%), unless otherwise stated. FVC: forced vital capacity; IPF: idiopathic pulmonary fibrosis; DLCO: diffusing capacity of the lung for carbon monoxide; HRCT: high-resolution computed tomography; UIP: usual interstitial pneumonia. #: in France, regulations did not permit the collection of data on race.